Laparoscopic Transhiatal Esophagectomy With Neoadjuvant Chemotherapy To Treat Carcinoma Of The Upper Esophagus | 3563
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Laparoscopic transhiatal esophagectomy with neoadjuvant chemotherapy to treat carcinoma of the upper esophagus

2nd International Conference on Gastroenterology & Urology

Shan Ma

AcceptedAbstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X.S1.019

Background: Esophagectomy for Carcinoma of the upper esophagus has traditionally been performed by open methods. Results from most series include mortality rates in excess of 5% and hospital stays frequently greater than 14 days. Laparoscopic transhiatal esophagectomy (LTHE) with neoadjuvant chemotherapy has the potential to improve these results and may lead to a sound outcome, but only a few articles have reported it. Objective: To investigate the method of LTHE with neoadjuvant chemotherapy treating cervical esophageal cancer. Methods: LTHE was performed in 5 patients with carcinoma of the upper esophagus. There were 4 men and 1 women. Median age was 64 years (range, 54?75). Indications for operation included high-grade dysplasia (n = 1) and cancer (n = 4). Neoadjuvant chemotherapy was used in 5 patients. Results: There was no conversion to open procedure. LTHE was successfully completed in 5 patients. The median intensive care unit stay was 1.5 days (range, 1?3); hospital stay was 10.5 days (range, 9?13). There was no anastomotic leak case happenning. At a mean follow-up of 13 months (range, 1?24), quality of life scores were similar to preoperative values and population norms. Conclusions: LTHE with neoadjuvant chemotherapy is a safe and relatively advanced, complex procedure with little blood loss and less-invasion. Its long-term outcome needs to be investigated with large-volume cases.